



# SAFETY DATA SHEET

Page 1 of 3

## SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

**Product:** CLAY-TITE™ MASTIC  
**Manufacturer:** W. R. MEADOWS OF CANADA  
**Part Number:** 5126-500  
**Address:** 70 Hannant Court  
Milton, Ontario Canada L9T 5C1  
**Telephone:** (905) 878-4122  
**Revision Date:** 1/9/2024  
**Product Use:** Patching Compound  
In case of emergency, dial (800) 424-9300 (CHEMTREC)

## SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS		HAZARD STATEMENTS
[Health]	1	<b>DANGER!</b>
[Flammability]	1	May cause cancer. (Category 1)
[Reactivity]	0	Causes skin irritation. (Category 2)
[Personal Protection]		Causes eye irritation. (Category 2B)
		May be harmful if inhaled. (Category 5)
		May cause damage to organs through prolonged/repeated exposures. (Category 2)
		May cause an allergic skin reaction. (Category 1A)
		<b>PRECAUTIONARY STATEMENTS</b>
		Avoid direct contact.
		Avoid dust inhalation.
		Use appropriate Personal Protective Equipment.



## SECTION 3: HAZARDOUS COMPONENTS

Chemical Name:	CAS Number	% by Weight	SARA 313	Vapor Pressure (mm Hg@20°C)	LEL (@25°C)
1. Microcrystalline Silicon Dioxide	14808-60-7	<1	No	N/A	N/A
2. Bentonite	1302-78-9	40-70	No	N/A	N/A
3. Hydrotreated Light Naphthenic Distillate	64742-53-6	30-60	No	N/A	N/A

N/A: Not Applicable

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313."

## SECTION 4: EMERGENCY AND FIRST AID PROCEDURES

**EYE CONTACT:** Immediately flush eyes with water for fifteen (15) minutes. If irritation persists, seek immediate medical attention.

**SKIN CONTACT:** Remove contaminated shoes/clothing. Flush affected areas with water. If irritation develops/persists, seek medical attention.

**INHALATION:** Remove victim from exposure source. Treat symptomatically. If symptoms persist, seek medical attention.

**INGESTION:** Do not induce vomiting. If vomiting spontaneously occurs, keep the head below the hips to prevent lung aspiration. Seek immediate medical attention.

**MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC:** See Section Eleven for Symptoms/Effects.

## SECTION 5: FIRE AND EXPLOSIVES HAZARDS

**FLASHPOINT:** 149 °C

**EXTINGUISHING MEDIA:** Water fog, foam, carbon dioxide, or dry chemical.

**CHEMICAL/COMBUSTION HAZARDS:** Carbon monoxide, carbon dioxide, and incomplete combustion products.

**PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT:** Avoid smoke inhalation. Use of full fire fighting equipment, including an SCBA, is recommended.

# SAFETY DATA SHEET

Date of Preparation: 1/9/24

Page 2 of 3

5126-500

## SECTION 6: ACCIDENTAL RELEASE MEASURES

**SPILL OR LEAK PROCEDURES:** Evacuate unauthorized personnel. Scrape up spilled material. Flush affected areas to remove clean-up residues. Place in marked/non-leaking containers for disposal.

## SECTION 7: HANDLING AND STORAGE

**SAFE HANDLING PROCEDURES:** Avoid direct contact with this material.

**SAFE STORAGE:** Store in cool, dry location. Keep containers closed when not in use.

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Chemical Name:	OSHA				ACGIH			
	PEL	PEL/CEILING	PEL/STEL	SKIN	TWA	TLV/CEILING	TLV/STEL	SKIN
1. Microcrystalline								
Silicone Dioxide <sup>+</sup>	*See Below	N/E	N/E	N/E	0.025 mg/m <sup>3</sup>	N/E	N/E	N/E
2. Bentonite <sup>+</sup>	N/E	N/E	N/E	N/E	N/E	N/E	N/E	N/E
3. Hydrotreated Light								
Naphthenic Distillate	2000 mg/m <sup>3</sup>	N/E	N/E	N/E	5 mg/m <sup>3</sup>	10 mg/m <sup>3</sup>	N/E	N/E
* : TWA Total Dust (30)/(%SiO <sub>2</sub> + 2) mg/m <sup>3</sup> TWA Respiratory Fraction (10)/(%SiO <sub>2</sub> + 2) mg/m <sup>3</sup> N/E: Not Established								
<sup>+</sup> : Product in paste form. No exposure anticipated, unless product is abraded.								

**ENGINEERING CONTROLS:** General ventilation is usually sufficient. Local exhaust systems may be used when general ventilation is inadequate.

**PERSONAL PROTECTIVE EQUIPMENT:** Safety glasses, chemical-resistant gloves.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<b>BOILING POINT:</b> 204 °C	<b>VAPOR DENSITY:</b> >1	<b>% VOLATILE BY VOLUME:</b> N/A
<b>EVAPORATION RATE:</b> N/A	<b>pH LEVEL:</b> N/A	<b>% VOLATILE BY WEIGHT:</b> 4
<b>WEIGHT PER GALLON:</b> 10	<b>PRODUCT APPEARANCE:</b> Brown Paste	<b>VOC CONTENT:</b> 48 g/L
<b>ODOR:</b> Mild Organic	<b>ODOR THRESHOLD:</b> N/D	<b>MELTING/FREEZING POINT:</b> N/D
<b>FLASH POINT:</b> See Section 5	<b>FLAMMABILITY:</b> N/D	<b>UEL/LEL:</b> N/D
<b>VAPOR PRESSURE:</b> N/D	<b>RELATIVE DENSITY:</b> N/D	<b>SOLUBILITY:</b> N/D
<b>PARTITION COEFFICIENT:</b> N/D	<b>AUTOIGNITION TEMPERATURE:</b> N/D	<b>DECOMPOSITION TEMPERATURE:</b> N/D
<b>VISCOSITY:</b> N/D	N/A = Not Applicable	N/D = Not Determined

## SECTION 10: STABILITY/REACTIVITY

**STABILITY:** Stable.

**HAZARDOUS POLYMERIZATION:** Will not occur.

**CONDITIONS AND MATERIALS TO AVOID:** Strong oxidizing agents

**HAZARDOUS DECOMPOSITION PRODUCTS:** None recognized.

## SECTION 11: TOXICOLOGICAL INFORMATION

**EYE CONTACT:** Direct contact may result in mild irritation.

**SKIN CONTACT:** May cause mild skin irritation. Sensitization reactions are possible.

**INHALATION:** Exposure may cause mild irritation of the nose, throat, respiratory tract, and other mucous membranes.

**INGESTION:** May cause mild to moderate irritation of the digestive tract.

**SIGNS AND SYMPTOMS:** Symptoms of eye exposure include pain, burning, redness, and swelling. Symptoms of skin irritation include redness, burning, swelling, and rash. Symptoms of respiratory irritation include runny nose, shortness of breath, chest discomfort, and reduced lung function. Symptoms of gastrointestinal exposure include abdominal pain, nausea, and vomiting.

**AGGRAVATED MEDICAL CONDITIONS:** Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product.

**OTHER HEALTH EFFECTS:** Silicon dioxide is listed by the IARC and NTP as being carcinogenic to humans (IARC Group 1A). Hydrotreated naphthenic distillate is listed as a confirmed human carcinogen (IARC Group 1A).

## SECTION 12: ECOLOGICAL INFORMATION

**ECOTOXICITY:** N/E

**DEGRADABILITY:** N/E

**BIOACCUMULATIVE POTENTIAL:** N/E

**SOIL MOBILITY:** N/E

**OTHER ADVERSE EFFECTS:** N/E

N/E: Not Established

## SAFETY DATA SHEET

Date of Preparation: 1/9/24

Page 3 of 3

5126-500

### SECTION 13: WASTE DISPOSAL INFORMATION

**WASTE DISPOSAL INFORMATION:** Not regulated as a hazardous waste in solid form. Landfill dispose.

### SECTION 14: TRANSPORTATION INFORMATION

**HAZARDOUS/NON-HAZARDOUS MATERIAL:** Non-hazardous material.

**UN NUMBER:** None.

**HAZARD CLASS:** None.

**PACKING GROUP:** None.

**UN PROPER SHIPPING NAME:** None.

**ENVIRONMENTAL HAZARDS:** None.

**BULK TRANSPORTATION INFORMATION:** Not applicable; product is not shipped in bulk configuration.

**SPECIAL PRECAUTIONS:** None.

### SECTION 14: TRANSPORTATION INFORMATION

**HAZARDOUS/NON-HAZARDOUS MATERIAL:** Non-hazardous material.

**UN NUMBER:** None.

**HAZARD CLASS:** None.

**PACKING GROUP:** None.

**UN PROPER SHIPPING NAME:** None.

**ENVIRONMENTAL HAZARDS:** None.

**BULK TRANSPORTATION INFORMATION:** Not applicable; product is not shipped in bulk configuration.

**SPECIAL PRECAUTIONS:** None.

### SECTION 15: REGULATORY INFORMATION

**OTHER REGULATORY CONSIDERATIONS:** None.

### SECTION 16: OTHER INFORMATION

**PREPARATION DATE:** 1/9/2024

**PREPARED BY:** Dave Carey

*The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.*